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What we CAN do about chronic allograft nephropathy: Role of
immunosuppressive modulations. Given the potency of mod-
ern immunosuppressive agents, kidney transplantation across
alloantingen barriers is a routine phenomenon with excellent
1-year graft survival in most centers. However, the improvement
in 1-year graft survival has not been matched by improvements
in long-term graft function and chronic allograft nephropathy
(CAN) remains the second commonest cause of graft attrition
over time. Calcineurin inhibitors, namely cyclosporine A (CyA)
and tacrolimus, have been implicated as causal agents in the de-
velopment of the fibrotic processes that are the hallmarks of
CAN. Many studies have, therefore, concentrated on the im-
provement of long term graft function through the modulation
of immunosuppressive therapy. It is the purpose of this review to
describe and appraise the available evidence for the prevention
and management of CAN through modulation of immunosup-
pressive agents.
Ever since the successful transplantation of human al-
lografts between identical twins by Murray et al almost
40 years ago, solid-organ transplantation has been an im-
pressive fusional achievement of scientific and surgical
collaboration. Technical and pharmacologic advances, in
particular the development and use of calcineurin in-
hibitors (CNIs), have made engraftment across alloanti-
gen barriers routinely achievable with much reduced risk
of acute rejection. Despite the recent introduction of new
and expensive immunosuppressive agents, however, im-
provements in allograft lifespan have lagged behind those
in 1-year survival (now routinely >90%) [1–4]. The two
most common causes of long-term graft loss remain death
with a functional graft, usually from a marked excess
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of cardiovascular mortality in allograft recipients, and
chronic allograft nephropathy (CAN), the term given to
the development of fibrotic processes leading to progres-
sive allograft dysfunction with variable proteinuria and
hypertension [5, 6]. It has been proposed that these two
processes may represent the systemic and local manifes-
tations of developing (micro- and macro-) vascular dis-
ease that are accelerated in the presence of a functioning
transplant and transplant immunosuppression. Indeed,
recent studies have demonstrated that progressive injury
to the renal microvasculature is among the first features
of developing CAN [7] and that renal functional decline
precedes the morphologic changes of CAN [8]. As such,
amelioration of one may play an important role in im-
provement or prevention of the other, although random-
ized controlled intervention studies to test this hypothesis
in renal transplantation have been scant [9].
The use of the term CAN, although convenient and
much employed in the literature and in clinical practice,
is a problem as it is a “catch-all” term. This observation
is not just semantic pedantry. There are (at least) two
processes, of different etiopathogenesis, that can occur
to a variable extent, and which can be labeled “CAN” as
the histopathologic findings overlap significantly. These
are chronic cyclosporine A (CyA) nephrotoxicity, and
chronic rejection. Interventions that may help the one
may exacerbate the other. It is the latter which is classi-
cally identified (as in the Banff classification) by the his-
tologic lesions of transplant glomerulopathy and arterial
intimal thickening. Insufficient attention to date has been
paid to understanding the relative contribution of each in
an individual’s case. Only recently have some important
clues to differentiate these two processes emerged, and
these need to be tested prospectively. These are peritubu-
lar/glomerular staining for C4d [10] and the production of
collagen 1 [11]. In the former case this is associated with
chronic transplant glomerulopathy (although this asser-
tion is itself the subject of speculation [12]), and in the
latter case chronic rejection. Further analysis of the dif-
ficulties in defining CAN fall outside the remits of this
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Table 1. Risk factors for the development of chronic allograft
nephropathy (CAN)
Alloantigen-dependent
Acute rejection episodes
Chronic subclinical rejection
Alloantigen-independent
Age, gender, and race of donor
Age, gender, and race of recipient
Type of transplant (nonheart-beating > heart-beating cadaveric
> live-related)
Diabetes
Hypertension
Hyperlipidemia
Length of time on dialysis
Ischemia/reperfusion injury
Cytomegalovirus infection
Drugs, in particular calcineurin inhibitors
Both alloantigen-dependent and alloantigen-independent mechanisms are
thought to play a part in the pathogenesis of the condition (synthesized from [12
to 19]).
article but it is important to note that the definitions for
CAN are not universal and that studies are therefore dif-
ficult to compare.
Although various risk factors for the development of
CAN have been identified, its pathogenesis is incom-
pletely defined (for an excellent article on this sub-
ject, please refer to [13]). Both alloantigen-dependent
and alloantigen-independent mechanisms are thought to
play a part in the pathogenesis of the condition [12–
19] (Table 1). Pilmore and Dittmer’s study, reported in
2002, showed that chronic CyA toxicity (defined as ex-
tensive arteriolar hyalinosis and obliteration), though
frequently colocalizing with glomerular and interstitial
fibrotic changes, was a separate entity, and although re-
nal function deteriorated progressively in patients with
or without chronic vascular changes, those patients with
chronic vasculopathy due to CNIs responded almost uni-
formly favorably to reduction in calcineurin inhibitor ex-
posure [22].
A recent paper from Jeremy Chapman’s group in Aus-
tralia, based on information from sequential protocol
biopsies, showed that there were two distinctive phases
of allograft injury. The first of these is a composite of
ischemic injury, prior acute rejection, and subclinical re-
jection. The second, usually more than 12 months posten-
graftment, is allograft injury characterized by high-grade
arteriolar hyalinosis, glomerulosclerosis, and tubulointer-
stitial scarring. In this study, additional tubulointerstitial
damage was found to accompany the use of CNIs [5],
which corroborated a recent analysis of 40,963 first kid-
ney transplant recipients between 1987 and 1996 from
the United States Renal Data System (USRDS). This lat-
ter paper identified a more rapid rate of decline in renal
function in patients on chronic CNI therapy [23], presum-
ably through mechanisms that either cause or exacerbate
CAN.
Because of the concerns that prolonged patient expo-
sure to calcineurin inhibitors was exacerbating or pro-
moting CAN [23, 24] there have been many trials in which
the aim has been to reduce CNI exposure. These have
included de novo avoidance of calcineurin inhibitor use,
phased calcineurin inhibitor withdrawal without drug ad-
ditions, substitution of one calcineurin inhibitor for an-
other, or the use of azathioprine, mycophenolate mofetil
(MMF), or sirolimus as calcineurin inhibitor–sparing
agents.
It is the purpose of this review succinctly and criti-
cally to describe and appraise the available evidence for
the prevention and management of CAN through mod-
ulation of immunosuppressive agents. As such, we hope
to guide the practicing transplant physician or surgeon
faced with the difficult clinical decisions necessary to help
patients with CAN. Central to our analysis of the avail-
able options will be three criteria: (1) the success of the
intervention at arresting renal function decline/rate of al-
lograft attrition, (2) the side-effect profile of any new im-
munosuppressive agents added, and (3) the rate of acute
or chronic rejection (and the graft loss therefrom), or
acute infectious complications, as a result of changes in
the overall potency of immunosuppression.
CALCINEURIN INHIBITORS
From their inception, CNIs have brought about a re-
markable reduction in transplant rejection and excellent
one-year graft survival. However, this has come at the
price of long-term graft dysfunction as the processes un-
derlying CAN seem intimately related to their use [23–
25]. The most common approach to prevent develop-
ment of CAN or to ameliorate it once developed is to
reduce exposure to CNIs by one of two methods, either
to reduce the delivered dose, which carries a risk of pre-
cipitating acute rejection, or to add in a different immuno-
suppressant while reducing or eliminating the calcineurin
inhibitor (so as to minimize the risk of acute rejection).
The study of Pascual et al [26] was instructive in demon-
strating that a 50% reduction in delivered dose of CNIs
in patients with stable renal function did not result in a
higher rate of acute rejection episodes compared to an
equal number of similar patients (N = 32) randomized
to continue same-dose CNI after 6 months of follow-
up. However, those randomized to dose reduction did
show improved blood pressure and lipid profiles. Simi-
larly, the randomized controlled trial of Abramowicz et al
[27] indicated that withdrawal of CyA from a triple im-
munosuppression protocol (MMF, steroid, and CyA) can
result in improved renal function and cardiovascular pro-
file at a cost of a modest increase in reversible acute re-
jection episodes (nine versus two subjects in withdrawal
and control arms, respectively) by the end of 6 months
of follow-up. However, in the setting of preventing CAN
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or of treating it once developed there is actually very lit-
tle evidence to support simple dose reduction in CNIs
without the addition of another agent. Perhaps the clos-
est is the study by Pilmore and Dittmer [22] from New
Zealand, which looked at 46 biopsies from patients who
had been transplanted for more than 6 months. Patients
were categorized into those with CAN alone (N = 16),
those with a combination of CAN and calcineurin in-
hibitor nephrotoxicity (CNIN; N = 21), and those with
neither nephrotoxicity nor CAN (N = 9). Patients with
evidence of nephrotoxicity had a significant dose reduc-
tion in CNI while those with CAN alone had no change in
therapy. After 17 months of follow-up, it was found that
patients with CNIN had a rapid improvement in renal
function within 1 month after dose reduction which was
sustained for the duration of follow-up, while those with
CAN alone had a gradual decline in renal function. Acute
rejection was not precipitated by the CNI withdrawal.
Unfortunately, this study did not incorporate dose reduc-
tion of CNI in CAN without active nephrotoxicity; there-
fore, it cannot differentiate whether the improvement in
graft dysfunction was the result of improvement in the
nephrotoxicity or of the CAN component (sometimes a
genuinely difficult clinical distinction to make).
CYCLOSPORINE AND TACROLIMUS: WHICH
CNI IS BETTER FOR CAN?
With regards to type of calcineurin inhibitor, there are
theoretical advantages of tacrolimus over CyA. Among
these, primary immunosuppression with a tacrolimus-
based regimen is associated with better cardiovascular
risk profile than a CyA-based regimen in nondiabetic
patients [28] (although there is no evidence that this im-
provement translates to reduced cardiovascular events)
and results in fewer and less severe acute rejection
episodes [29]. These advantages are reviewed in de-
tail elsewhere [30] but have prompted investigation into
substitution of tacrolimus for CyA. Studies can essen-
tially be divided into those comparing the effects of
tacrolimus versus CyA as primary immunosuppression
on the propensity to develop CAN and those compar-
ing a secondary switch from CyA to tacrolimus once
CAN has developed. Murphy et al [31] carried out a
prospective randomized trial using either tacrolimus or
microemulsion CyA (Neoral) together with azathioprine
in 102 nonheart-beating renal allografts. At 1 year, trans-
plant interstitial fibrosis was quantified using comput-
erized histomorphometric measurement of picro sirius
red-staining on protocol biopsies. There was a signifi-
cant increase in allograft interstitial fibrosis in the pa-
tients treated with Neoral compared with those given
tacrolimus in the absence of differences in acute rejec-
tion episodes, steroid-resistant rejection, or pretransplan-
tation risks for CAN. This study was corroborated by
that of Jurewicz [32], who analyzed 6-year follow-up data
from 232 renal transplant recipients randomized to treat-
ment with tacrolimus or CyA. Renal function, as de-
termined by the glomerular filtration rate (GFR), was
significantly better in tacrolimus-treated patients from
month 3 posttransplant and normal renal function was
maintained throughout a 5-year follow-up in a signifi-
cantly higher proportion of nonrejecting patients treated
with tacrolimus than with CyA (58% versus 10%, respec-
tively, at 5 years; P = 0.002). As with the previous study,
analysis of protocol biopsies revealed that the degree of
interstitial fibrosis, similar in both treatment groups at
baseline, was significantly greater in the CyA group af-
ter 12 months. Furthermore, they found that patients re-
ceiving tacrolimus had significantly greater 6-year graft
survival (81% versus 60%; P = 0.0496) and a higher
projected graft half-life (15 versus 10 years) than those
receiving CyA. Moreover, both studies identified better
lipid profiles and cardiovascular risk in the tacrolimus co-
hort patients than their CyA-treated counterparts.
A recent report from Turkey blindly scutinizing pro-
tocol biopsies carried out in the first 6 months posttrans-
plant in 35 patients randomized to either tacrolimus or
CyA concluded that, although the incidence of acute re-
jection episodes may not be significantly different be-
tween the two groups, subclinical acute rejection and
subclinical CAN was more common with CyA than
tacrolimus [33] (although their findings did not reach sta-
tistical significance, possibly in view of the small sam-
ple size). These differences in histology may well be
explained by the differential expression of genes encod-
ing extracellular matrix material in transplant glomeruli
between patients given tacrolimus versus those given
CyA as primary immunosuppression. Indeed, Bicknell
et al [34] have shown a persistent increase in mRNA
encoding type II collagen and tissue inhibitor of matrix
metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) [but
not transforming growth factor-b1 (TGF-b1)] in 51 trans-
plant biopsies of patients on CyA compared to those on
tacrolimus from as early as the first week posttransplant.
Some of their early findings could undoubtedly be ac-
counted for by differences in biopsy material and the
source of the transplant (living or cadaveric donor). How-
ever, the same observations were made on the 6-month
protocol biopsies, making it likely that the expression of
matrix components is more favored by the presence of
CyA than tacrolimus.
Unfortunately, all these studies have been carried out
over a relatively short period of time and with small pa-
tient numbers. Therefore, the likelihood of deriving a
beneficial result by chance alone is relatively high. Fur-
thermore, there is no guarantee that histologic studies
carried out at 6 months or a year will correlate with the de-
velopment of CAN over the next few years. These prob-
lems are highlighted by a detailed multivariate analysis of
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the USRDS, which demonstrated comparable 3-year
graft survival for both cadaveric and living donor re-
nal transplant patients receiving either CyA-Neoral or
tacrolimus with MMF and steroids, with no significant dif-
ferences between treatment groups. They included 9449
patients in the multivariate analysis (2130 on tacrolimus
and 7319 on CyA) pooling data from 1995 to 1998 [35].
Similarly, the FK506 Kidney Transplant study Group
failed to demonstrate a difference between CyA and
tacrolimus in the likelihood of developing CAN on pro-
tocol biopsies carried out at 2 years postengraftment in
144 subjects [36].
Substituting tacrolimus for CyA once CAN has de-
veloped is another therapeutic option. Results for this
approach have been mixed and there was, in general, a
paucity of data in the literature until very recently. An
early, cross-sectional pilot study by Jurewicz [37] followed
14 patients with biopsy-proven CAN for 15 months af-
ter a switch from CyA to tacrolimus. They reported two
distinct responses. One group, comprising nine patients,
demonstrated continued deterioration in the estimated
GFR, while the second group, of five patients, showed an
improvement (who extended their return to dialysis by
a median of 41 months). In contrast, the trial conducted
by Stoves at al [38] from the United Kingdom showed
that substitution of tacrolimus for CyA in patients with
biopsy proven CAN and declining renal function had no
advantage over continued CyA over a 6-month follow-up
period [36], although it could be argued that the length of
follow-up was insufficient and that the study, comprising
14 patients in each group, was underpowered to detect
small differences between them.
More recently, the group of Lee et al [39] retrospec-
tively analyzed a heterogeneous cohort of 34 renal trans-
plant recipients who had had biopsy proven acute cellular
rejection or CAN and who had been switched from CyA
to tacrolimus. Up to 72 months of follow-up later, a con-
sistent pattern of improved renal function and slowing of
renal functional decline was observed in comparison to
baseline. Blood pressure control was also improved. Also
very recently, the publication of Waid et al reported on a
group of 186 subjects fulfilling clinical criteria for CAN
(90% with baseline biopsy demonstrating CAN) who had
had a switch from CyA to tacrolimus in a 2:1 ratio. After
2 years of follow-up, serum creatinine was significantly
better in the tacrolimus treated cohort (which was better
than at baseline) while acute rejection episodes and allo-
graft survival was similar. A further 3 years of follow-up
is planned for these patients [40]. A similar but smaller
study, unsupported by renal biopsy, comprising 30 sub-
jects, demonstrated comparable results up to three years
of follow-up [41].
Given the small patient numbers in the trials high-
lighted above and the clinical heterogeneity of patients in
some of them, it is difficult to be certain whether substitu-
tion of tacrolimus for CyA will reduce the risk of CAN in
the long term and whether this switch may be of benefit
for secondary prevention. The body of evidence for the
latter approach has been increasing in the recent past but
the majority of studies have, quite rightly, concentrated
on substituting a noncalcineurin inhibitor for CyA.
AZATHIOPRINE
Azathioprine has long been used as a steroid spar-
ing agent in a variety of clinical scenarios. Switching
from CyA to azathioprine in stable renal allografts has
previously been demonstrated to improve cardiovas-
cular risk profile and incidence of gout [42, 43]. The
natural postulate is whether it can be used as a cal-
cineurin inhibitor–sparing agent in order to reduce the
incidence of CAN. One animal study using Fisher kid-
neys transplanted into bilaterally nephrectomized Lewis
rats (i.e., high immunogenic risk) [44] employed a CyA-
based induction protocol followed by switch at day 11
to either CyA and prednisolone, azathioprine and pred-
nisolone, or vehicle and prednisolone. Organs harvested
at 24 weeks for morphology and immunohistochemistry,
however, demonstrated no difference between the CyA
or azathioprine-based immnosuppression protocols in
the development of changes of CAN. It is, however, diffi-
cult to be certain as to what extent this model reflects the
human disease and difficult to know whether the length of
exposure to the various agents was sufficient to demon-
strate a difference between them. Furthermore, groups
consisted of only eight rats each, such that heterogene-
ity in immune responsiveness between individuals could
well have skewed the results.
Azathioprine is a less potent immunosuppressive agent
than CyA; there was therefore a higher incidence of acute
rejection in the pre-CyA era using azathioprine-based
protocols. The trial of MacPhee et al [45] demonstrated
that azathioprine can be used in patients with stable allo-
graft function as early as the first year posttransplantation
to permit CNI withdrawal with the benefit of improved
graft function but at a cost of increased acute rejection
episodes in the first few months postswitch. As such, hu-
man data comparing the risks of developing CAN us-
ing azathioprine as primary agent versus CyA are scant.
However, there are several historic studies using azathio-
prine to modify the risk of developing “CyA toxicity” and
“chronic rejection” in existing CNI–based regimens. Un-
fortunately, many of these studies were carried out in the
pre-Banff era, so it is difficult to be certain as to the le-
sional correlation between “chronic rejection” and what
was later defined as CAN. Furthermore, without classi-
fication of severity, it is possible that their populations
of “chronic rejection” could have been of low severity
and therefore more likely to respond to treatment. Sweny
et al [46] randomized a cohort of 77 nondiabetic stable
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cadaveric renal transplants at 1 year to either convert
from CyA to azathioprine or to continue CyA. Patients
were subsequently followed up for 12 months. An im-
provement in reciprocalized serum creatinine and an
improvement in blood pressure control were noted in
the 33 patients randomized to conversion. However,
nine of these individuals experienced acute rejection,
of whom six returned to CyA. On the other hand, six
patients randomized to continue CyA had to switch
to azathioprine as a result of CyA toxicity. CyA lev-
els remained unchanged in those continuing CyA but
serum creatinine levels demonstrated a progressive de-
cline with time. Pascual et al [47] added azathioprine
to an ongoing CyA-prednisone protocol in 31 patients
without reducing dose of CyA. Subjects were a mean of
11.3 months after renal transplantation and were sub-
sequently followed up for a mean of 23 months. Pa-
tients were split into three groups: those with “chronic
rejection,” those with repeated episodes of acute rejec-
tion, and those with CyA toxicity despite dose reduction.
In the first group, serum creatinine had risen over the
6 months prior to azathioprine (renal function declining
at a rate of −0.13 ± 0.12 creatinine−1/month) but im-
proved at a rate of 0.05 ± 0.07 creatinine−1/month in the
6 months postazathioprine and at a rate of 0.05 ± 0.12
creatinine−1/month during the entire follow-up period
(P < 0.01); CyA levels remained stable. The second group
had a greater decline in renal function but this was ar-
rested after addition of azathioprine. In group three, re-
nal function improved in eight patients. At the end of the
study, 15 patients had improved graft function, two were
stable, 12 had worsened (nine on dialysis), and two had
died. It is interesting to note the improvement of allograft
dysfunction in all three groups simply by the addition of
further immunosuppression and rather surprising in the
last group with CyA toxicity. Unfortunately, the results
of this study have never been repeated.
More recently, Bakker et al [48] carried out an open-
labeled randomized trial of conversion from CyA to aza-
thioprine at 3 months posttransplant with 128 patients
allocated to either continued CyA or switch to azathio-
prine. At 2 years posttransplant, graft survival and GFR
were already significantly better in those on azathioprine
and the risk of developing CAN was lower [relative risk
for CyA 4.3 (95% CI 1.4 to 12.9) (P = 0.009)]. Further-
more, more biopsies from those on CyA showed fea-
tures of nephrotoxicity which prompted a late switch. At
15 years of follow-up, graft survival was higher in the aza-
thioprine arm (76.5% versus 64.7%), although this did
not reach statistical significance until the data were ana-
lyzed according to patients staying on assigned treatment
(i.e., not by intention-to-treat). Acute rejection rates were
scarce in this context but many fewer patients were on
blood pressure and lipid-lowering medications at the end
of the study. Unfortunately, the small patient numbers
and failure to demonstrate a significant difference in graft
survival by intention-to-treat analysis argue that the dif-
ference between CyA and azathioprine on the basis of
this trial was actually quite small. Indeed, conversion to
azathioprine carries an increased risk of early rejection
[49], which is why patients enrolled into this study also
had a temporary increase in steroid dose to cover the
transitional period.
With regard to using azathioprine to treat “chronic
CyA nephropathy,” the study of Mourad et al [50] fol-
lowed up a cohort of 23 patients with biopsy-proven
chronic CyA nephropathy who were given azathioprine
and had either dose reduction (18 of 23) or cessation (5
of 23) of CyA. At the end of 2 years follow-up, they ob-
served a significant improvement in GFR (mean 40 to
47 mL/min) with concomitant improvement in serum cre-
atinine. Blood pressure, likewise, improved. One episode
of reversible acute rejection was documented.
Dosing of azathioprine is generally done by sub-
ject weight (and not by drug levels) and its effects
are governed by metabolism to its active metabolite 6-
mercaptopurine (6-MP) via the thiopurine methyltrans-
ferase (TPMP) enzyme system. Its clinical efficacy and
adverse effects profile correlate very well with tissue lev-
els of 6-MP, although some idiosyncratic reactions have
also been known to occur. There is more than 40 years
of experience with this drug, and generally it is very well
tolerated.
On the basis of a propensity to precipitate acute re-
jection and the weaknesses of trials highlighted above, it
would appear then that azathioprine is less than ideal as
a CNI–sparing agent. In addition, the lack of published
negative data (which is suggestive of the process of publi-
cation bias) and the paucity of further positive trials may
indicate that the effects of azathioprine on developing
CAN could be much worse than the available literature is
currently suggesting. However, more potent immunosup-
pressants have since emerged and have prompted similar
investigations.
MMF
MMF is a more potent immunosuppressive agent than
azathioprine [51] and has supereded azathioprine in
many centers for primary immunosuppression in com-
bination with a CNI and steroid [52]. It acts as a prodrug
whose active metabolite inhibits the activity of inosine
monophosphate dehydrogenase (IMPDH), a key enzyme
in the generation of purines in the S phase of the cell cycle.
As such, it has an antiproliferative effect (e.g., on smooth
muscle cells) that may be useful in preventing or treat-
ing the scarring processes underlying CAN. Additionally,
MMF inhibits the expression of adhesion molecules on
endothelial cells, thereby retarding infiltration by inflam-
matory cells [53], increases apoptosis of T lymphocytes
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[54], and reduces antibody production from B cells
[55]. Indeed, a prospective randomized trial by Merville
et al [56] evaluating the likelihood of developing biopsy-
proven CAN at 1 year in patients on a CyA-based pro-
tocol randomized to include either azathioprine or MMF
demonstrated that the incidence of CAN was significantly
lower in patients on MMF (31% versus 63%). CyA lev-
els were the same between the two groups. Therefore,
on the assumption that calcineurin-free protocols would
reduce the incidence of CAN through primary preven-
tion and in vitro experiments showing that MMF inhibits
activation of human mesangial cells [57], several studies
have looked at the use of MMF as a calcineurin-sparing
agent for primary prevention of CAN. Initially, Vincenti
et al [58] carried out a multicenter, open-label, cohort
study using a protocol of daclizumab, MMF, and corticos-
teroids. A total of 98 primary kidney transplant recipients
of low immunologic risk were given 2 mg/kg daclizumab
before transplantation and 1 mg/kg for a fortnight (for
a total of five doses), MMF 3 g/day for 6 months fol-
lowed by 2 g/day thereafter and conventional corticos-
teroid. Almost 50% of patients experienced an episode
of biopsy-proven acute rejection by 6 months. Neverthe-
less, 1-year graft and patient survival were still 97% and
96%, respectively, at a cost of initiating calcineurin in-
hibitors in 62% of the patients as a result of acute rejec-
tion. Mean serum creatinine at 1 year was 113 lmol/L
(1.57 mg/dL) in nonrejectors and 154 in patients who ex-
perienced rejection and were then started on a calcineurin
inhibitor. At 1 year, 16% of patients who had protocol
biopsies showed histologic evidence of CAN. These pa-
tients showed significantly lower expression of TGF-b ,
fibronectin, and collagen than a cohort of CNI–treated
historic controls. Tran et al [59] conducted a very sim-
ilar prospective, nonrandomized, open-label trial using
the same agents in favor of CNI in 45 kidney transplant
recipients. The immunusuppression protocol was identi-
cal to the previous study except for tapering prednisolone
to 15 mg/day instead of 10 mg/day at 6 months. Again,
there was a high incidence of biopsy-proven acute rejec-
tion (approximately one third of patients) although graft
and patient survival remained excellent (95% and 100%,
respectively). CyA was eventually started on 51% of pa-
tients as a result of acute rejection or intolerance of MMF
or steroids. These individuals had a higher serum creati-
nine [mean 168 versus 106 lmol/L (1.9 versus 1.2 mg/dL)]
and required more antihypertensive medications.
Early conversion at 3 months from a CyA-based reg-
imen to a CyA-free regimen using MMF and steroid as
maintenance treatment was subsequently assessed by an
open randomized trial by Schnuelle et al [60]. Their co-
hort of 84 renal transplants converted at 3 months post-
transplantation showed better creatinine clearance (71.7
versus 60.9 mL/min) and calculated GFR (73.2 versus
61.9 mL/min) at the end of 1 year in comparison to those
subjects randomized to continue CyA. However, acute
rejection episodes were again found to occur with greater
frequency after withdrawal of CyA (11.3% versus 5.0%).
Although these papers are encouraging in that they
provide histologic evidence of reduced expression of fi-
brogenic genes (albeit in very small numbers of patients)
and demonstrate that a proportion of patients can be
maintained CNI–free, they lack control data and the ele-
ment of randomization. Furthermore, the high incidence
of acute rejection is unsatisfactory and could actually in-
crease the risk of developing CAN in the longer term,
particularly since most of the subjects recruited into these
trials were of low immunogenic risk.
The risk of acute rejection, however, reduces with time,
permitting dose reduction or even cessation of certain im-
munosuppressants. The question, then, is whether MMF
can be added as an adjunct into a CNI–based regimen
to allow dose reduction or cessation of the CNI without
precipitating acute rejection and whether this maneuver
results in improved graft survival. Several studies have
now demonstrated that the introduction of MMF and the
reduction or withdrawal of CyA have a favorable out-
come in the setting of CAN (see Table 2). Although there
are animal experiments in abundance [61], the first sig-
nificant clinical description in the literature of altering
the immunosuppressive regimen involving MMF to treat
CAN was by Weir et al in 2001 [62]. They studied 118
patients with declining renal function and biopsy-proven
CAN in whom CNIs were reduced in 100 and discontin-
ued completely in 18, and in whom MMF was initiated at
a dose of 2 g/day [although, in the event, the eventual ad-
ministered doses were mostly in the range 1.2 to 1.5 g daily
(for largely unspecified reasons)]. At a mean follow-up of
651 days after the intervention, improvement in renal
function was evident in the majority of patients as judged
by amelioration of slopes of reciprocalized serum creati-
nine or lack of deterioration in the slopes. The interven-
tion was well tolerated and episodes of acute rejection
were scant.
Francois et al [63] recently reported a controlled study
of the use of 2 g daily MMF in 39 patients with CAN us-
ing conventionally treated patients as controls. Although
there was an improvement in serum creatinine in the
switch group at 1 year and 3 years in comparison to base-
line (the control group showed no change in creatinine
over time), graft survival was comparable between the
two groups. Furthermore, they noted a high incidence of
abdominal symptoms, systemic infections, and anemia, all
signs of excessive immunosuppression with MMF, which
led to discontinuation in two case and dose reduction
in 18. This trial was mirrored by that of Ducloux et al
[64] whose regimen of substituting MMF for Aza and
withdrawing CyA in 31 patients with CAN demonstrated
improved serum creatinine after conversion, which
remained stable after a mean follow-up of 27 months
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Fig. 1. Mean reciprocalized serum creatinine
(1/creatinine) before and after introduction
of mycophenolate mofetil (MMF) over a 12-
month run-in and follow-up period. A total of
89 patients with established chronic renal al-
lograft nephropathy (CAN) were started on a
regimen of MMF at a median dose of 1 g/day
with phased reduction in delivered dose of
CNIs over a 12-month period. The 95% con-
fidence bands for the regression lines are de-
picted. This dose was very well tolerated and
only 7 out of 89 patients stopped MMF as a
result of adverse effects. Only one episode of
acute rejection was observed.
[227 ± 31 lmol/L versus 185 ± 50 lmol/L (2.55 ± 0.35
versus 2.01 ± 0.56 mg/dL; P < 0.0005)]. However, they
also reported a high incidence of infection (28% of pa-
tients) with the 2 g daily dosing regimen, an observation
that was repeated by Khatchatryan et al [65], who found
that it was difficult to exceed 1.5 g/day of MMF without
troublesome side effects. This difficulty was also evident
in the recently reported and elegantly designed “creeping
creatinine study,” where 144 subjects with CAN were ran-
domized to two groups. The first group was initiated on a
combination of steroid and MMF titrated up to 2 g with
elimination of CyA, while the second group continued
CyA as previously. Patients in the first group showed a sig-
nificant stepwise improvement in 1/creatinine at 6 months
and maintained this improvement to the end of the study
at 12 months, while subjects in the second group con-
tinued to show deteriorating graft function. Two grafts in
the first group and four in the second were lost during the
study period but there were no acute rejection episodes.
Unfortunately, there was an 85% incidence of adverse
events with a daily dose of 2 g of MMF, particularly gas-
trointestinal, infective, and hematologic events [66]. Our
own observations aimed at elucidating the effectiveness
and tolerability of lower doses of MMF (mean of 1 g/day)
over the long term have shown that lower doses of MMF
are very well tolerated without precipitating episodes of
acute rejection and lead to improved graft function that
are maintained in the long term [67] (Fig. 1).
Although the above studies nearly all demonstrate im-
proved graft function and/or graft survival, a number of
caveats exist. First, most studies have been carried out in
small numbers of patients, without the element of ran-
domization and over short periods of time. The study of
Weir et al, who demonstrated good tolerance of MMF
consisted of a majority of African Americans, whose im-
munogenetics are known to be different to other popu-
lations, so the recorded responses may not necessarily be
comparable to those of other cohorts. The lack of good
meta-analyses is a demonstration of the heterogeneity
of study protocols and the difficulty in translating data
from these small patient populations to larger, different
ones. Furthermore, it is unclear whether it is the addi-
tion of MMF per se which results in improved outcome
or the reduction/withdrawal of CNI. This latter question
has in part been addressed by two studies, carried out
by Henne et al [68] and the Spanish Cooperative Study
Group of Chronic Allograft Nephropathy [69]. The re-
port by Henne et al in children with CAN exposed to
1.2 mg/m2 of MMF without a change in CNI level showed
a favorable allograft functional outcome at the price of
significant (mainly gastrointestinal) side effects. Their co-
hort of 36 children showed no significant change in trough
CyA levels at 1 year (114 ng/mL before and 98 ng/mL at
1 year after) [68]. The Spanish study recruited 121 patients
with biopsy-proven CAN, 59 of whom were on treatment
with CyA and prednisolone and 62 of whom were re-
ceiving CyA, prednisolone, and azathioprine. Each group
was given 2 g per day of MMF and azathioprine was
stopped. Renal function as judged by Cockcroft-Gault
GFR remained stable during the (median) 36 months
of follow-up while the slope of the GFR improved. In
65 patients whose CyA levels had remained unchanged
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during follow-up, there was a reduction in the rate of loss
of GFR [69]. Both of these studies are suggestive that
the addition of MMF was responsible for ameliorating
transplant function since the CyA levels and exposure re-
mained unchanged. However, both studies consisted of
small numbers of subjects and the latter’s findings were
the result of a subanalysis, which would increase the likeli-
hood of deriving a statistically significant result by chance
alone. One additional complexity of altering CNI dosage
in the context of MMF is the complex pharmacokinetic
interactions between these classes of immunosuppressive
drugs. The efficacy and side-effect profile of MMF is re-
lated to trough mycophenolic acid (MPA) levels [70].
There are significantly lower levels of plasma MPA for
the same MMF dosage in patients taking CyA compared
to patients on tacrolimus [69]. Given these interactions
it would seem advantageous for MMF doses to be deter-
mined by MPA blood levels in future trials. Additionally,
the findings of these two studies is refuted by those of
Suwelack et al [71], who carried out the only trial to date
of adding in MMF to a CNI–based regimen in the con-
text of established CAN and then randomizing patients
to either withdrawing or continuing with the CNI. The
trial was stopped prematurely as a significant difference
in renal function was found in an interim analysis which
strongly favored the withdrawal of CNI.
A reasonable number of small studies have so far pro-
vided data for the use of MMF to allow dose reduction or
cessation of CNIs in the setting of CAN and the data are
on the whole quite encouraging. Nevertheless, one must
bear in mind the possibility of publication bias, particu-
larly since nearly all available investigators have reported
positive findings. Furthermore, these findings have not
yet been subjected to a large multicenter randomized,
double-blinded trial due to the unethical nature of carry-
ing out a placebo-controlled study in this setting and the
difficulty in achieving double blinding (given that drug
levels will need to be monitored).
SIROLIMUS
Sirolimus acts by binding to FK-binding protein
(FKBP) and the SRL-FKBP complex then inhibits
mTOR (mammalian target of rapamycin) and by so doing
blocks the downstream signal transduction pathways re-
quired for progression of a cell from G1 to the S phase of
the cell cycle. It thus acts as a potent immunosuppressive
and antiproliferative agent with the properties of inhibit-
ing fibrogenesis, a function that maybe useful in prevent-
ing the scarring processes observed in CAN. The advent
of sirolimus has, therefore, prompted renewed enthusi-
asm in primary prevention of CAN by using sirolimus-
based regimens to avoid calcineurin inhibitors (Table 3).
Animal experiments have highlighted its ability, in com-
bination with MMF, to prevent the features of CAN,
namely fibrous intimal thickening, allograft glomerulopa-
thy, and interstitial fibrosis [72, 73]. As a result, a random-
ized open-label, multicenter trial recruited 78 cadaveric
renal allograft recipients of low immunologic risk and
randomized them to treatment with sirolimus or CyA,
in combination with MMF and steroids [74]. Sirolimus
was administered to achieve a level of 30 ng/mL for the
first 2 months and 15 ng/mL thereafter, while CyA was
dosed to achieve trough levels of 200 to 400 ng/mL for
2 months and 100 to 200 ng/mL after that. The dose of
steroids and MMF was the same in both groups but MMF
was discontinued at 6 months for both groups with an
option to convert to azathioprine if needed. They iden-
tified no significant difference in patient and graft sur-
vival or in biopsy-proven acute rejection after 12 months
of follow-up. However, from 2 months onwards, cal-
culated GFR was consistently higher in the sirolimus
arm. A higher incidence of hypercholesterolemia, hy-
pertriglyceridemia, thrombocytopenia, and diarrhea was
found in the sirolimus-treated patients, the latter two be-
ing adverse effects of MMF (sirolimus increases levels
of MPA). Very similar results have previously been pub-
lished by the Sirolimus European Renal Transplant Study
Group, which compared sirolimus to CyA for primary
immunosuppression, in combination with azathioprine
and steroid [75] using virtually identical protocols. In-
deed, the 2-year results of these two trials were later an-
alyzed together and demonstrated that serum creatinine
was consistently lower in sirolimus-treated groups who
had a calculated GFR that was on average 10 mL/min
better [76]. Even aiming for lower levels of sirolimus and
CyA as in the study of Flechner et al [77] (target level of
10 to 12 ng/mL for 6 months and 5 to 10 ng/mL thereafter
for sirolimus and 200 to 250 ng/mL for CyA) but using in-
duction therapy with basiliximab, no difference in acute
rejection episodes or graft survival was found between
sirolimus and CyA groups but sirolimus-treated patients
had better calculated GFR (81.1 ± 23.9 mL/min versus
61.1 ± 14.6 mL/min; P < 0.01). Adverse effect profiles
in this study were not different. The observed beneficial
effects of this therapy were consistent in these patients
who were then reanalyzed at 2 years postengraftment.
GFR remained significantly better in the sirolimus arm
and, of the 48 patients who were rebiopsied, 67% versus
21% had normal (Banff 0) biopsies when compared to
the CyA arm [78].
One other option is to transplant as per current pro-
tocols using a CNI and, once the early rejection-prone
period is over, to convert from CNI to sirolimus in or-
der to reduce the long-term probability of developing
CAN. The multicenter trial of Johnson et al [79] used CyA
in combination with low dose sirolimus as primary im-
munosuppression and then randomized subjects to either
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discontinue CyA (with dose increase in sirolimus) or
to continue on it. One-year graft (and patient) survival
was similar with comparable acute rejection episodes, al-
though a slight increase in acute rejection was observed
at the time of CyA withdrawal. Patients on sirolimus
had better GFRs than those maintained on CyA which
was sustained over the 2-year follow-up. The Rapamune
Maintenance Regimen Trial adopted a similar approach
with stable allograft recipients on a triple immuno-
suppression regimen of sirolimus/CyA/steroid random-
ized at 3 months to continue or to withdraw CyA. At
36 months of follow-up, significantly better calculated
GFR (59 versus 47 mL/min) was observed in the with-
drawal arm together with a tendency to improved graft
survival. Adverse effect profiles included predictably in-
creased rate of hypertension, abnormal kidney function,
edema, hyperuricemia, hyperkalemia, gingival hyperpla-
sia, and Herpes zoster occurred significantly in the CyA
continuation arm and abnormal liver function test results,
hypokalemia, thrombocytopenia, and abnormal healing
in the withdrawal arm [80]. Similar studies from Spain
and Italy showed that a significantly lower rate of biopsy
features of progressive tubular and interstitial chronic le-
sions between basal and 1-year biopsies was evident on
using this approach [81] and that fewer patients were di-
agnosed with biopsy-proven CAN [82].
Since tacrolimus in combination with MMF is associ-
ated with fewer episodes of acute rejection than CyA
[83], several studies have looked at the combination
of tacrolimus and sirolimus. Ciancio et al [84] random-
ized 150 first-transplant patients to receive tacrolimus
and sirolimus, tacrolimus and MMF or Neoral and
sirolimus. Each group received daclizumab at induction
and steroids. Tacrolimus levels were tapered in the first
group to 10, 8, and 6 ng/mL at 1, 6, and 12 months, re-
spectively, and in the second group to 10 and 8 ng/mL
at 1 month and 1 year, respectively. CyA levels were
maintained at 225 and 175 ng/mL at 1 month and 1 year,
while sirolimus levels remained unchanged at 8 ng/mL
throughout. At 1 year, acute rejection was higher in the
CyA group than in the others (14% versus 4% versus
4%; P = 0.03), although patient and graft survival were
identical [77]. CyA-treated patients showed rising slopes
of serum creatinine and concomitantly reducing creati-
nine clearance at 1 year. Patients on sirolimus required
more antihyperlipidemic medications than those on
MMF [85].
Although these studies seem to indicate favorable out-
comes for sirolimus in the short term, they do not ad-
dress the problem of long-term allograft nephropathy,
although the low incidence of acute rejection episodes,
avoidance of CNIs and low 1-year serum creatinine [86]
should improve long-term outlook. Unfortunately, sig-
nificant selection bias exists as individuals recruited into
these studies were of low immunogenic risk; hence, these
results might not generalize to a more heterogeneous
transplant population. Side-effect profiles appear to be
a double-edged sword as amelioration of hypertension
off CNIs is often at a cost of excessive hyperlipidemia on
sirolimus, an important effect as cardiovascular mortality
remains the number one cause of death. Nevertheless, the
observations are encouraging and have formed the basis
for further trials.
A small number of investigators have also studied the
role of sirolimus in allowing dose reduction in CNIs once
CAN has already developed. The trial of Saunders et al
[87] recruited 31 patients with biopsy-proven CAN and
randomized them to receive dose reduction in CyA (by
40%) with or without addition of sirolimus (2 mg/day).
CyA trough levels were similar in the two groups but
patients on sirolimus had a significant fall in 51 crea-
tinine GFR (from 31.6 to 27.3 mL/min) at the end of
the 6-month follow-up period, whereas controls did not.
mRNA extraction from biopsy specimens showed that
expression of TGF-b actually dropped in controls but re-
mained constant on sirolimus while collagen expression
actually increased in sirolimus-treated patients. These
results are somewhat surprising given the well-known
antiproliferative effects of sirolimus and should prompt
further investigation using larger patient cohorts. More
recently, Bumbea et al reported the findings of an in-
vestigation of 43 renal transplant recipients who were
switched from CNIs to sirolimus due to either CAN or
recurrent cutaneous cancers. All patients were addition-
ally on steroids together with either MMF or azathio-
prine. Unfortunately, after 27 months of follow-up, only
59% of subjects were still on sirolimus. Intention-to-treat
analysis demonstrated a sustained improvement in renal
function at a cost of developing significant proteinuria in
up to one third of subjects [88]. Although this is a small
study, the high discontinuation rate is worrying.
Sirolimus, though of immense promise, has only re-
cently been widely used, has very little experience in es-
tablished CAN patients, and has a significant side-effect
profile at least when used at conventional dose/blood
level ranges. These can be idiosynchratic or dose-related
effects such as edema, joint pains, skin rashes, mouth
ulcers, pneumonitis, liver function disturbance, dys-
lipidemia, thrombocytopenia, and thrombotic microan-
giopathy [89, 90]. Nevertheless, sirolimus remains a useful
adjunct immunosuppressant and the trials presented
above have provided encouraging results for its use as
primary immunosuppression in favor of CNIs or as an
early switch a few months after transplantation. Its ex-
act role in transplantation has yet to be established and
will have to be the subject of further clinical trials with
larger populations of more varied immunogenetics and
immunologic risk. Further work on the use of sirolimus
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once CAN has already developed should follow on the
basis of the limited trial data already published.
CONCLUSION
CAN remains a very important and common cause of
graft loss and a difficult clinical problem to tackle. Al-
though many studies have been carried out in hetero-
geneous patient populations and involving addition or
manipulation of a number of different agents, in general,
subjects have been carefully selected and small in num-
ber. So this is quite unlike “clinical practice.” More at-
tention needs to be paid to which histologic markers at
allograft biopsy best predict a favorable outcome follow-
ing on from manipulation of immunosuppression. Ad-
ditionally, there is significant interobserved variation in
the classification of CAN according to the Banff criteria
[91]. Making conducting clinical research a more difficult
task because different degrees of fibrosis may respond
diversely to manipulation of immunosuppression.
Furthermore, nearly all trials present short-term data,
with only a few reporting long-term findings, using plasma
creatinine or GFR as a surrogate marker for long-term
survival prospects. One would indeed hope that short-
term improvement will translate to long-term gain but
this is by no means a certainty. Firm conclusions on trials
with these limitations are therefore difficult to make. Cer-
tainly, if the pathologic process seems intimately related
to the use of calcineurin inhibitors, it would appear log-
ical to switch from CNI to non-CNI–based protocols at
least once CAN has developed especially since trial data
on switching from CyA to tacrolimus are limited and still
unconvincing. A corollary of this philosophy is the use of
protocol implantation followed by allograft biopsies at 3
to 6 months postengraftment to detect increasing fibrosis
or subclinical CAN (rather than waiting for progressive
allograft dysfunction) on the basis of which drug therapy
can be altered as above. Alternatively, one could try to
avoid CNI exposure from the outset. Though this sounds
reasonable, it too should be subjected to the rigor of a
randomized controlled trial.
Azathioprine carries an excess risk of acute rejection
during a switch from CyA but seems on the basis of lim-
ited data to ameliorate CyA toxicity and to improve lipid
profiles and blood pressure control by allowing dose re-
duction or withdrawal of CNI. However, the studies using
azathioprine are quite limited and therefore its effects on
long-term graft survival, development, and progression
of CAN cannot be firmly stated.
MMF has had perhaps the most significant amount
of investigation, with most papers demonstrating an im-
provement in graft function at least in the short term
without precipitating rejection episodes, although pub-
lication bias may be playing a role here. Unfortunately,
there are very few long-term data and most trials have
used relatively large doses of MMF (of the order of
2 g/day), thereby reporting high incidences of adverse
effects. Given the interactions between MMF and CNIs,
we would suggest monitoring of MPA levels in future tri-
als in order to individualize MMF doses for patients. The
evidence that the use of MMF is, per se important (as op-
posed to its nonspecific permissive role in allowing a re-
duction in CNI exposure) needs confirmation with more
precisely designed trials addressing this point. Clearly
in 2006 many transplantation centers now routinely use
MMF therapy at induction, so in this case simple CNI
reduction or withdrawal should be relatively straightfor-
ward to achieve.
Investigations into sirolimus have so far been rela-
tively encouraging, with demonstration of its efficacy in
the short term to substitute for CNIs or to allow lower
doses to be used without an increase in acute rejection
episodes. However, there are limited long term results
on using sirolimus in lieu of calcineurin inhibitors once
CAN has developed and therefore this approach cannot
yet be strongly recommended. The side-effect profile of
this drug at conventional doses is a cause for concern.
Using the three criteria we outlined in the
introduction—the success of the intervention at ar-
resting renal function decline, the side-effect profile of
any new immunosuppressive agents added (including
acute infectious complications as a result of changes in
the overall potency of immunosuppression), and the rate
of acute or chronic rejection (and subsequent graft loss),
we feel that the present evidence best favors the reduc-
tion/elimination of CNI under MMF cover. We must
enter the caveat, however, that much more clinical infor-
mation and trial evidence is required before the definitive
approach to the prevention or treatment of CAN can
be recommended. These concerns are in the process of
being addressed with a series of ongoing switch studies
aimed at answering the question of whether switching
from or reducing CNI combined with introduction of
MMF, sirolimus, or everolimus may save renal transplant
function or reduce the progression of CAN. These trials
include the ongoing Trancept and Intercept Studies
(MMF, ongoing), the EliTE-symphonie study (MMF,
ongoing), the 316 sirolimus study (sirolimus, ongoing),
and the ASCERTAIN Trial (everolimus, recruiting). In
the meantime, while awaiting the completion of these
trials, it would appear reasonable to reduce doses of
CNIs once CAN has developed and to substitute another
agent to prevent acute rejection. MMF, given that it has
the largest share of clinical data thus far would seem to
be an appropriate first choice agent.
Finally, important though the impact of altering im-
munosuppression may be, it must be remembered that
there are many shared non-immunologic risk factors be-
tween CAN and cardiovascular disease, which remains
the most important cause of death and graft loss. It is
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important therefore to try and control these as well,
in particular anemia, hypertension, proteinuria, and hy-
perlipidemia, and the importance of control of blood
pressure [92] as well as adjunctive therapies such as
angiotensin-converting enzyme (ACE) inhibitors [93]
and statins [9] cannot be overstated. There are differences
between immunosuppressive compounds regarding risk
factors for cardiovascular disease and it is perhaps an-
other argument for the metabolically neutral MMF over
the cholesterol-raising sirolimus and the prohyperten-
sive, diabetogenic, and prodyslipidemic CNI. However,
one must note that there is no evidence that such differ-
ences really translate into differences in real cardiovas-
cular events.
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